247 related articles for article (PubMed ID: 19744643)
41. Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer.
de Groot JW; Links TP; Jager PL; Kahraman T; Plukker JT
Ann Surg Oncol; 2004 Aug; 11(8):786-94. PubMed ID: 15289241
[TBL] [Abstract][Full Text] [Related]
42. Comparison of (18)F-FDG, (131)I-Na, and (201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma.
Shiga T; Tsukamoto E; Nakada K; Morita K; Kato T; Mabuchi M; Yoshinaga K; Katoh C; Kuge Y; Tamaki N
J Nucl Med; 2001 Mar; 42(3):414-9. PubMed ID: 11337516
[TBL] [Abstract][Full Text] [Related]
43. 18F-FDG PET reduces unnecessary hemithyroidectomies for thyroid nodules with inconclusive cytologic results.
de Geus-Oei LF; Pieters GF; Bonenkamp JJ; Mudde AH; Bleeker-Rovers CP; Corstens FH; Oyen WJ
J Nucl Med; 2006 May; 47(5):770-5. PubMed ID: 16644746
[TBL] [Abstract][Full Text] [Related]
44. ¹⁸F-FDG and new positron emitter radiotracers for detecting recurrent medullary thyroid carcinoma.
Marzola MC; Rubello D
J Med Imaging Radiat Oncol; 2012 Apr; 56(2):132-5. PubMed ID: 22498183
[No Abstract] [Full Text] [Related]
45. 18F-fluorodeoxyglucose positron emission tomography-computed tomography for suspected recurrent papillary thyroid cancer: early experience at Sunnybrook Health Sciences Centre.
Dahele M; Ung YC; Ehrlich L; Silverberg J; Balogh J; Wong CS
J Otolaryngol Head Neck Surg; 2008 Oct; 37(5):712-7. PubMed ID: 19128681
[TBL] [Abstract][Full Text] [Related]
46. F-18-FDG-PET in a patient with Hashimoto's thyroiditis and MALT lymphoma recurrence of the thyroid.
Mikosch P; Würtz FG; Gallowitsch HJ; Kresnik E; Lind P
Wien Med Wochenschr; 2003; 153(3-4):89-92. PubMed ID: 12658970
[TBL] [Abstract][Full Text] [Related]
47. Preoperative FDG-PET imaging to assess the malignant potential of follicular neoplasms of the thyroid.
Smith RB; Robinson RA; Hoffman HT; Graham MM
Otolaryngol Head Neck Surg; 2008 Jan; 138(1):101-6. PubMed ID: 18165002
[TBL] [Abstract][Full Text] [Related]
48. Usefulness of [99mTC]MIBI and [18F]fluorodeoxyglucose for imaging recurrent medullary thyroid cancer and hyperparathyroidism in MEN 2a syndrome.
Roelants V; Michel L; Lonneux M; Lacrosse M; Delgrange E; Donckier JE
Acta Clin Belg; 2001; 56(6):373-7. PubMed ID: 11881324
[TBL] [Abstract][Full Text] [Related]
49. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels.
Ong SC; Schöder H; Patel SG; Tabangay-Lim IM; Doddamane I; Gönen M; Shaha AR; Tuttle RM; Shah JP; Larson SM
J Nucl Med; 2007 Apr; 48(4):501-7. PubMed ID: 17401085
[TBL] [Abstract][Full Text] [Related]
50. Clinical relevance of 18F-FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma.
Verbeek HH; Plukker JT; Koopmans KP; de Groot JW; Hofstra RM; Muller Kobold AC; van der Horst-Schrivers AN; Brouwers AH; Links TP
J Nucl Med; 2012 Dec; 53(12):1863-71. PubMed ID: 23081996
[TBL] [Abstract][Full Text] [Related]
51. How has the management of medullary thyroid carcinoma changed with the advent of 18F-FDG and non-18F-FDG PET radiopharmaceuticals.
Wong KK; Laird AM; Moubayed A; Chondrogiannis S; Marzola MC; Evangelista L; Gross MD; Rubello D
Nucl Med Commun; 2012 Jul; 33(7):679-88. PubMed ID: 22422100
[TBL] [Abstract][Full Text] [Related]
52. FDG-PET in head and neck, and thyroid cancer.
Macapinlac HA
Chang Gung Med J; 2005 May; 28(5):284-95. PubMed ID: 16086543
[TBL] [Abstract][Full Text] [Related]
53. Clinical significance of focal and diffuse thyroid diseases identified by (18)F-fluorodeoxyglucose positron emission tomography.
Salvatori M; Melis L; Castaldi P; Maussier ML; Rufini V; Perotti G; Rubello D
Biomed Pharmacother; 2007 Sep; 61(8):488-93. PubMed ID: 17604940
[TBL] [Abstract][Full Text] [Related]
54. High incidence of thyroid cancer in focal thyroid incidentaloma detected by 18F-fluorodeoxyglucose [corrected] positron emission tomography in relatively young healthy subjects: results of 3-year follow-up.
Ohba K; Nishizawa S; Matsushita A; Inubushi M; Nagayama K; Iwaki H; Matsunaga H; Suzuki S; Sasaki S; Oki Y; Okada H; Nakamura H
Endocr J; 2010; 57(5):395-401. PubMed ID: 20160400
[TBL] [Abstract][Full Text] [Related]
55. Hepatocellular carcinoma eats medullary thyroid carcinoma, a case of tumor-in-tumor metastasis.
Sung TY; Lee SR; Lee JH; Lee YM; Lee AL; Hwang DW; Yoon JH; Gong G; Hong SJ; Park KM
Endocr J; 2011; 58(9):801-5. PubMed ID: 21757828
[TBL] [Abstract][Full Text] [Related]
56. Role of 18F-FDG-PET and PET/CT imaging in thyroid cancer.
Nanni C; Rubello D; Fanti S; Farsad M; Ambrosini V; Rampin L; Banti E; Carpi A; Muzzio P; Franchi R
Biomed Pharmacother; 2006 Sep; 60(8):409-13. PubMed ID: 16891093
[TBL] [Abstract][Full Text] [Related]
57. Oncocytic adenomas of thyroid-mimicking benign or metastatic disease on 18F-FDG-PET scan.
Zandieh S; Pokieser W; Knoll P; Sonneck-Koenne C; Kudlacek M; Mirzaei S
Acta Radiol; 2015 Jun; 56(6):709-13. PubMed ID: 24948789
[TBL] [Abstract][Full Text] [Related]
58. Focal uptake of fluorodeoxyglucose by the thyroid in patients undergoing initial disease staging with combined PET/CT for non-small cell lung cancer.
Yi JG; Marom EM; Munden RF; Truong MT; Macapinlac HA; Gladish GW; Sabloff BS; Podoloff DA
Radiology; 2005 Jul; 236(1):271-5. PubMed ID: 15987980
[TBL] [Abstract][Full Text] [Related]
59. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
[TBL] [Abstract][Full Text] [Related]
60. Cytologic diagnosis of recurrent medullary thyroid carcinoma with oncocytic change twenty-one years post-thyroidectomy: case report and review of the literature.
Tranchida P; Estigarribia J; Sethi S; Giorgadze T
Diagn Cytopathol; 2011 Sep; 39(9):641-6. PubMed ID: 20949456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
